Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
2008 1
2009 1
2013 1
2014 1
2015 1
2016 1
2017 5
2018 2
2019 5
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

19 results
Results by year
Filters applied: . Clear all
Page 1
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition.
Cretella D, Digiacomo G, Giovannetti E, Cavazzoni A. Cretella D, et al. Among authors: digiacomo g. Cancers (Basel). 2019 Sep 6;11(9):1318. doi: 10.3390/cancers11091318. Cancers (Basel). 2019. PMID: 31500143 Free PMC article. Review.
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S, Minari R, Cretella D, Flammini L, Fumarola C, Bonelli M, Cavazzoni A, Digiacomo G, Galetti M, Madeddu D, Falco A, Lagrasta CA, Squadrilli A, Barocelli E, Romanel A, Quaini F, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. Among authors: digiacomo g. J Exp Clin Cancer Res. 2019 May 28;38(1):222. doi: 10.1186/s13046-019-1240-x. J Exp Clin Cancer Res. 2019. PMID: 31138260 Free PMC article.
Fibronectin induces macrophage migration through a SFK-FAK/CSF-1R pathway.
Digiacomo G, Tusa I, Bacci M, Cipolleschi MG, Dello Sbarba P, Rovida E. Digiacomo G, et al. Cell Adh Migr. 2017 Jul 4;11(4):327-337. doi: 10.1080/19336918.2016.1221566. Epub 2016 Sep 2. Cell Adh Migr. 2017. PMID: 27588738 Free PMC article.
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells.
Cretella D, Fumarola C, Bonelli M, Alfieri R, La Monica S, Digiacomo G, Cavazzoni A, Galetti M, Generali D, Petronini PG. Cretella D, et al. Among authors: digiacomo g. Sci Rep. 2019 Sep 10;9(1):13014. doi: 10.1038/s41598-019-49484-4. Sci Rep. 2019. PMID: 31506466 Free PMC article.
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
La Monica S, Minari R, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Galetti M, Digiacomo G, Riccardi F, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. Among authors: digiacomo g. Target Oncol. 2019 Oct;14(5):619-626. doi: 10.1007/s11523-019-00669-x. Target Oncol. 2019. PMID: 31502118
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
Bonelli MA, Digiacomo G, Fumarola C, Alfieri R, Quaini F, Falco A, Madeddu D, La Monica S, Cretella D, Ravelli A, Ulivi P, Tebaldi M, Calistri D, Delmonte A, Ampollini L, Carbognani P, Tiseo M, Cavazzoni A, Petronini PG. Bonelli MA, et al. Among authors: digiacomo g. Neoplasia. 2017 Aug;19(8):637-648. doi: 10.1016/j.neo.2017.05.003. Epub 2017 Jul 11. Neoplasia. 2017. PMID: 28704762 Free PMC article.
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.
La Monica S, Cretella D, Bonelli M, Fumarola C, Cavazzoni A, Digiacomo G, Flammini L, Barocelli E, Minari R, Naldi N, Petronini PG, Tiseo M, Alfieri R. La Monica S, et al. Among authors: digiacomo g. J Exp Clin Cancer Res. 2017 Dec 4;36(1):174. doi: 10.1186/s13046-017-0653-7. J Exp Clin Cancer Res. 2017. PMID: 29202823 Free PMC article.
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
Cavazzoni A, Digiacomo G, Alfieri R, La Monica S, Fumarola C, Galetti M, Bonelli M, Cretella D, Barili V, Zecca A, Giovannetti E, Fiorentino M, Tiseo M, Petronini PG, Ardizzoni A. Cavazzoni A, et al. Among authors: digiacomo g. Cancers (Basel). 2020 Mar 12;12(3):666. doi: 10.3390/cancers12030666. Cancers (Basel). 2020. PMID: 32178474 Free PMC article.
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR.
Castelli R, Bozza N, Cavazzoni A, Bonelli M, Vacondio F, Ferlenghi F, Callegari D, Silva C, Rivara S, Lodola A, Digiacomo G, Fumarola C, Alfieri R, Petronini PG, Mor M. Castelli R, et al. Among authors: digiacomo g. Eur J Med Chem. 2019 Jan 15;162:507-524. doi: 10.1016/j.ejmech.2018.11.029. Epub 2018 Nov 13. Eur J Med Chem. 2019. PMID: 30472599
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacomo G, Cavazzoni A, Alfieri R, Biondi A, Generali D, Bonelli M, Petronini PG. Cretella D, et al. Among authors: digiacomo g. J Exp Clin Cancer Res. 2018 Mar 27;37(1):72. doi: 10.1186/s13046-018-0741-3. J Exp Clin Cancer Res. 2018. PMID: 29587820 Free PMC article.
19 results
Jump to page
Feedback